Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

September 29 - October 3, 2021; Virtual
Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.
Darcy Wooten, MD
Released: October 11, 2021

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

  • A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
  • Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
  • Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
  • Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
  • Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
  • The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Information on this Educational Activity

Faculty

Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Commentary on lessons learned during the COVID-19 pandemic for reducing barriers to HIV prevention service access, from Clinical Care Options (CCO)

Latesha Elopre, MD, MSPH Michael A. Fordham, BA Released: December 7, 2021

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue